Reaction tray and noncontact transfer method for heterogeneous chemiluminescence immunoassays.

We describe a reaction tray for a heterogeneous chemiluminescence (CL) immunoassay having the following features: separate sample incubation and signal detection wells; a design that allows for noncontact transfer of the reaction mixture from incubation wells to detection wells; surface features to mate with a detector and create a light-tight seal for CL detection; and self-contained means for liquid removal. The reaction mixture is transferred by injecting a wash solution from a group of nozzles into the incubation well. Quantitative transfer of microparticles (transfer efficiencies greater than 95% and CV less than 5%) is achieved by injecting two 300-microL pulses of transfer solution at a rate of 2.

Abbott prism: a multichannel heterogeneous chemiluminescence immunoassay analyzer.

We describe a multichannel heterogeneous immunoassay analyzer in which a sample is split between disposable reaction trays in a group of linear tracks. The system's pipettor uses noninvasive sensing of the sample volume and disposable pipet tips. Each assay track has (a) a conveyor belt for moving reaction trays to predetermined functional stations, (b) temperature-controlled tunnels, (c) noncontact transfer of the reaction mixture between incubation and detection wells, and (d) single-photon counting to detect a chemiluminescence (CL) signal from the captured immunochemical product.

Detection apparatus for multiple heterogeneous chemiluminescence immunoassay configurations.

We describe an apparatus for measuring signals emanated from two heterogeneous chemiluminescence immunoassay (CLIA) configurations: antibody-coated polystyrene beads, in reaction tray wells, and microparticles captured by a porous matrix. An optics and fluidics design which allows the use of a common detection head for these two different assay configurations is described. The detection head moves along three Cartesian coordinates to create a localized light-tight compartment around each individual disposable reaction vessel.

[Randomized comparison between gallopamil and diltiazem in angiography verified coronary heart disease].

In a randomized study 30 patients (age 59 +/- 7) with angiographically confirmed coronary artery disease were treated with either gallopamil (15 patients) or diltiazem (15 patients). After a 48-h-run-in period of treatment with nitrates the gallopamil group was treated with 3 X 60 mg/day, and the diltiazem group was treated with 3 X 50 mg diltiazem/day. As criteria for the efficacy of therapy the anginal frequency, the nitroglycerin consumption, and exercise tolerance were monitored.